NuGene International, Inc. Names Donna Queen To Board Of Directors

IRVINE, CA--(Marketwired - June 02, 2015) - NuGene International, Inc. ("NuGene") (OTCQB: NUGN), a developer, manufacturer and marketer of advanced skin and hair care lines utilizing adipose derived human stem cells and stem cell media, has announced that Ms. Donna Queen has accepted a position on NuGene's Board of Directors.

Ms. Queen's experience spans the biotechnology, cosmeceutical, consumer packaged goods and vision care industries and includes working with Allergan, Revlon, Bausch & Lomb, Arm & Hammer and DuPont. Her knowledge of the cosmeceutical industry was further enhanced while serving as the President of Lifeline Skin Care and ZO Skin Health.

"We are excited to welcome Donna Queen to the Board and to draw on her expertise as a seasoned cosmeceutical executive and respected leader in our industry as we build our markets for our NuGene product offerings," stated Ali Kharazmi, President and CEO of NuGene. "Ms. Queen will bring the same thoughtful leadership advice and sage insights to NuGene that she delivered so effectively and successfully in the past. Combining her experience with Fortune 500 brands with an innovative entrepreneurial spirit and creative mindset makes her a perfect addition to our Board of Directors. I am confident that she will make a meaningful and immediate contribution to our Board and company."

In accepting the Board position Ms. Queen noted, "The anti-aging skincare market is saturated with brands with copycat ingredients. Professionals and consumers alike are desperate for new technologies that are breakthrough, proprietary and -- most importantly -- proven. NuGene has been able to align these features and I believe our brand will stand apart and lead in a crowded marketplace."

Ms. Queen was able to attract substantial media attention for Lifeline® Stem Cell Skin Care while building an internationally recognized and respected brand. As president and CEO of ZO Skin Health by Zein Obagi, MD, she established a global brand presence and secured distribution in prestigious retailers such as Nordstrom, along with Ritz Carlton and Four Seasons spas. She also led ZO's successful e-commerce program.

Ms. Queen's personal skin care product experience includes cosmeceutical products (M.D. Formulations®, M.D. Forte®, Valeant's Kinerase®); physician-dispensed skincare products (Obagi® Nu-Derm) and Rx skincare products (Allergan Tazorac® for acne and psoriasis, Allergan Fluoroplex® for actinic keratoses) and lasers for hair removal and for the treatment of spider and varicose vein corrective procedures. She has expertise in multiple channels of distribution, including professional (plastic surgeons, dermatologists and spas), Direct To Consumer (online and home shopping) and retail (department stores, mass merchant, food and drug and specialty retail).

Ms. Queen has also directed corporate communications and marketing initiatives as both an executive and a consultant to various industries. She brings the ability to conceive, develop and exploit marketing strategies that allow brands to stand out in saturated marketplaces. As the founder, President and CEO of Communique Marketing from 1993 to 2007, Ms. Queen propelled the agency to become the recognized source for launching and growing cosmeceutical brands.

About NuGene International, Inc.

NuGene International, Inc. specializes in developing, manufacturing and marketing proprietary regenerative cosmeceutical and pharmaceutical products based on adipose derived human stem cell and human stem cell media. The US Department of Health and Human Services calls regenerative medicine the "next evolution of medical treatments." The regenerative medical market which includes cosmeceuticals and pharmaceuticals was estimated at $7.2 Billion in the US in 2014 and is expected to rapidly grow in the coming years according to RNCOS Business Consultancy Services Global Cosmeceuticals Market report. NuGene's cosmeceutical and pharmaceutical products are based on proprietary stem cell based regenerative formulations derived from non-controversial, adult human stem cell derived media obtained from adipose tissue. NuGene's exclusive products combine its in-house advancements, proprietary technologies, and patent pending formulations. The company has four patents pending covering 15 unique applications and inventions. NuGene's goal is to leverage its knowledge and expertise to develop age defying cosmeceutical skincare and hair care products in addition to pharmaceutical products based on the same regenerative science platform.

Forward-Looking Statements

This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by NuGene International may not proceed as contemplated, and by all other matters and assumptions specified in NuGene's filings with the Securities and Exchange Commission, especially those risks and other matters described under "Risk Factors" within NuGene's Form 10-Q filed with the Commission on May 15, 2015. These statements are made based upon current expectations that are subject to risk and uncertainty. NuGene does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. 

Investor/ Media Relations:
Chris Rosgen
Capital Market Relations
(949) 481-9739